Peer-reviewed articles published as first-author and correspondence
1. Lim do H, Im YH, Ji SH, Park BB, Oh MJ, Lee J, Park KW, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Lee MH, Kim K, Shim YM, Park K.
Esophageal squamous cell carcinoma recurring as a solitary renal mass.
Cancer Res Treat. 2004;36:271-4.
2. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Cancer Chemother Pharmacol. 2005;56:10-4.
3. Lim do H, Lee J, Lee HG, Park BB, Peck KR, Oh WS, Ji SH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Park K.
Pulmonary complications after hematopoietic stem cell transplantation.
J Korean Med Sci. 2006;21:406-11.
4. Lim do H, Kim HS, Park YS, Lee J, Park SH, Lim HY, Ji SH, Park MJ, Yi SY, An JY, Sohn TS, Noh JH, Bae JM, Kim S, Park CK, Kang WK.
Metastatic lymph node in gastric cancer; is it a real distant metastasis?
BMC Cancer. 2010:29;10:25.
5. Lim do H, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, Kwon JM, Lee SC, Lee HY, Kim HS, Lim HY, Kang WK.
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.
BMC Cancer. 2010;10:583.
6. Kim ST, Lim do H, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO.
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Mol Cancer Ther. 2011;10:1993-9.
